These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7545308)
1. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Silén A; Wiklund B; Andersson EL; Nilsson S Scand J Clin Lab Invest; 1995 Apr; 55(2):153-61. PubMed ID: 7545308 [TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue. Gion M; Mione R; Barioli P; Sartorello P; Capitanio G Eur J Clin Chem Clin Biochem; 1994 Oct; 32(10):779-87. PubMed ID: 7865616 [TBL] [Abstract][Full Text] [Related]
3. The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Bodenmüller H; Donié F; Kaufmann M; Banauch D Int J Biol Markers; 1994; 9(2):70-4. PubMed ID: 7523544 [TBL] [Abstract][Full Text] [Related]
4. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients. Miédougé M; Devys A; Simon M; Rouzaud P; Salama G; Reyre J; Pujazon M; Carles P; Serre G Tumour Biol; 2001; 22(1):19-26. PubMed ID: 11054023 [TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Stieber P; Schmeller N; Schambeck C; Hofmann K; Reiter W; Hasholzner U; Fateh-Moghadam A Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259 [TBL] [Abstract][Full Text] [Related]
6. Development of a new Prolifigen TPA IRMA assay using monoclonal anti-cytokeratin antibodies. Sundström BE; D'Amico Y; Brundell J Int J Biol Markers; 1995; 10(3):166-73. PubMed ID: 8551060 [TBL] [Abstract][Full Text] [Related]
7. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21]. Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636 [TBL] [Abstract][Full Text] [Related]
8. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Correale M; Arnberg H; Blockx P; Bombardieri E; Castelli M; Encabo G; Gion M; Klapdor R; Martin M; Nilsson S Int J Biol Markers; 1994; 9(4):231-8. PubMed ID: 7836801 [TBL] [Abstract][Full Text] [Related]
9. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
10. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of a cytokeratin 19 assay kit "BALL ELSA CYFRA21-1"]. Sakahara H; Kousaka T; Hattori N; Hosono M; Kobayashi H; Shirato M; Yao Z; Konishi J Kaku Igaku; 1993 Dec; 30(12):1475-9. PubMed ID: 7509008 [TBL] [Abstract][Full Text] [Related]
12. The correlation between serum levels of cytokeratin tumor markers does reflect their molecular characterization. Gion M; Mione R; Barioli P; Sartorello P; Dal Zennaro E; Gasparini C; Marconato R Int J Biol Markers; 1994; 9(2):121-2. PubMed ID: 7523542 [No Abstract] [Full Text] [Related]
13. Evaluation of a new tumor marker for cytokeratin 8 and 18 fragments in healthy individuals and prostate cancer patients. Silén A; Wiklund B; Norlén BJ; Nilsson S Prostate; 1994 Jun; 24(6):326-32. PubMed ID: 7516071 [TBL] [Abstract][Full Text] [Related]
14. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. van Dalen A Anticancer Res; 1996; 16(4B):2345-9. PubMed ID: 8694567 [TBL] [Abstract][Full Text] [Related]
15. [A basic and clinical evaluation of a new immunoradiometric assay kit for human serum tissue polypeptide antigen (TPA)]. Shimojo K; Watanabe N; Sakai S; Kobayashi M; Ohtake H; Hatori N; Fukasawa K; Tomiyoshi K; Inoue T; Endo K Kaku Igaku; 1996 Jun; 33(6):655-61. PubMed ID: 8741511 [TBL] [Abstract][Full Text] [Related]
16. Serum TPS versus TPA in Egyptian bladder cancer patients. Halim AB; el-Ahmady O; Hamza S; Aboul-Ela M; Oehr P Int J Biol Markers; 1993; 8(4):221-6. PubMed ID: 7511149 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of BEKI TPS radioassay kit as a one-step immunoradiometric assay utilizes monoclonal and polyclonal antibodies specific for serum tissue polypeptide antigen]. Hamase A; Kawanaka M; Kitani H; Fukuchi M Kaku Igaku; 1994 Aug; 31(8):995-1003. PubMed ID: 7933689 [TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
19. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer]. Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748 [TBL] [Abstract][Full Text] [Related]
20. In vitro effect of contrast agents during immunoradiometric assay for tumour-associated antigens. Watanabe N; Oriuchi N; Higuchi T; Yukihiro M; Fukushima Y; Tomiyoshi K; Hirano T; Inoue T; Endo K Nucl Med Commun; 1998 Jan; 19(1):63-70. PubMed ID: 9515548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]